Benzocaine otic solution

Drug Profile

Benzocaine otic solution

Alternative Names: AR-01

Latest Information Update: 16 Apr 2015

Price : $50

At a glance

  • Originator Arbor Pharmaceuticals
  • Class Aminobenzoic acids; Benzoates; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 23 Jun 2014 Discontinued - Phase-III for Pain (In adolescents, In children) in USA (Otic)
  • 01 Mar 2014 Arbor Pharmaceuticals completes a phase III trial in Otitis media (in paediatric patients) in USA (NCT02044341)
  • 31 Dec 2013 Arbor Pharmaceuticals initiates enrolment in two phase III trials for Otitis media (in paediatric patients) in USA (NCT02044341 & NCT02074007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top